4//SEC Filing
Saad Kareem 4
Accession 0001209191-23-058263
CIK 0001818331other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 4:05 PM ET
Size
10.0 KB
Accession
0001209191-23-058263
Insider Transaction Report
Form 4
Saad Kareem
Chief Business Officer
Transactions
- Sale
Class A Common Stock
2023-12-11$1.61/sh−850$1,369→ 20,532 total - Exercise/Conversion
Restricted Stock Unit
2023-12-09−2,841→ 34,090 total→ Class A Common Stock (2,841 underlying) - Exercise/Conversion
Class A Common Stock
2023-12-09+2,841→ 21,382 total
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Documents
Issuer
GeneDx Holdings Corp.
CIK 0001818331
Entity typeother
Related Parties
1- filerCIK 0001873805
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 4:05 PM ET
- Size
- 10.0 KB